











The oncolytic peptide LTX-315, which has been de novo designed based on structure–
activity relationship studies of host defense peptides, has the ability to kill human 
cancer cells and induce specific anticancer immune response when injected locally into 
tumors established in immunocompetent mice. The oncolytic effect of LTX-315 involves 
perturbation of plasma membrane and the mitochondria with subsequent release of 
danger-associated molecular pattern molecules, which highlights the ability of LTX-
315 to induce complete regression and protective immune responses. Treatment with 
LTX-315 reprograms the tumor microenvironment by decreasing the local abundance 
of immunosuppressive cells and by increasing the frequency of effector T cells.
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Host defense peptides, often also denoted 
antimicrobial peptides or cationic antimi-
crobial peptides (CAPs) since most of them 
are abundant in cationic residues, constitut-
ing an important part of the innate immune 
system and are present in virtually all species 
of life [1–3]. To date, more than 2800 antimi-
crobial peptides isolated from species ranging 
from bacteria, fungi, plants to mammals have 
been reported and are curated in the Anti-
microbial Peptide Database [4]. Their most 
studied function is the defense against bacte-
ria and, consequently, a number of naturally 
occurring and synthetic analogues have been 
evaluated in clinical trials as future antibiot-
ics [5]. The antimicrobial activity has in many 
cases been ascribed to peptide–membrane 
interactions, in which negatively charged 
constituents on bacterial surfaces have been 
implied as the initial targets for interaction 
with cationic side chains on CAPs. CAPs 
have also been found to cross the bacterial 
membrane to act on intracellular targets [6]. 
It is not uncommon for CAPs to also dem-
onstrate cytotoxic activity against cancer 
cells at concentrations that are not toxic to 
normal cells [7,8], which can be explained by 
a higher abundance of anionic membrane 
components on cancer cells compared with 
normal cells [7,8]. Thus, CAPs may display a 
level of selectivity not commonly displayed 
by  chemotherapeutic drugs.
Several different models describing the 
peptide–lipid interactions leading to mem-
brane disruption by CAPs have been sug-
gested [9–15], and the ability to adopt amphipa-
thic structures with separated cationic (Lys 
and Arg residues) and hydrophobic regions 
(Val, Leu, Ile, Phe and Trp residues) has been 
established as important [16,17]. Furthermore, 
some of the CAPs demonstrate immuno-
modulatory activities such as chemo taxis and 
an induction of cytokine release (see [18] for a 
recent review).
Bovine lactoferricin (LfcinB) [19] is a 
well-studied 25 amino acid CAP that dis-
plays selective antimicrobial and anticancer 
properties [20–22]. This peptide is derived 
from the pepsin-mediated hydrolysis of the 
iron-binding bovine glycoprotein lactofer-
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Figure 1.  Structure of LTX-315. (A) Amino acid sequence of LTX-315 (K-K-W-W-K-K-Dip-K-NH2); (B) 3D representation of an idealized 
helical conformation of LTX-315.  
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rin [19,23], and is present in exocrine secretions such 
as milk, saliva and in the secretory granules of neu-
trophils [20]. LfcinB contains residues 17–41 of the 
parent lactoferrin protein, and has a cyclic structure 
due to a disulphide bond between two Cys residues. 
In the bovine lactoferrin protein, residues 17–28 
comprise a helical segment [24], whereas the 25-mer 
peptide adopts a twisted antiparallel β-sheet struc-
ture in solution [25]. Noteworthily, both structures 
are highly amphipathic. While the linear version of 
LfcinB proved to be less active than the cyclic par-
ent peptide [21], linear analogs with a high cytotoxic 
activity could be obtained by focusing on the helical 
part of the parent protein. Through these studies, it 
has further been confirmed that an amphipathic sec-
ondary structure as well as the nature, size and posi-
tioning of aromatic amino acids is of importance for 
 activity [26–28].
The vast amount of SAR-data on lactoferricin-
derived, and also synthetic model peptides has facili-
tated the de novo design of 9-mer cationic peptides in 
which counterproductive residues have been deleted 
and the properties of residues identified as important 
for anticancer activity have been optimized, thereby 
resulting in a series of 9-mers composed of five cationic 
residues, two or three tryptophan residues and one or 
two bulky and lipophilic unnatural residues [29]. These 
peptides were found to be highly effective against both 
drug-resistant and drug-sensitive cancer cells, and dis-
played a lower activity toward normal cells. One of 
the candidates developed, named ‘LTX-315’ (Figure 1) 
displayed selective anticancer activity in preclinical 
 studies.
LTX-315 has been shown to be highly active against 
a wide variety of both murine and human cancer cell 
lines in vitro [29–34].
Discussion
In recent years, immunogenic cell death (ICD) has 
emerged as a new concept in cancer therapy [35]. ICD 
is initiated by the release of so-called danger-associated 
molecular pattern molecules (DAMPs) such as calre-
ticulin, ATP and high mobility group box protein 1 
(HMGB1), and has the potential of stimulating an 
immune response against antigens derived from dying 
cancer cells [35]. Further, only cancer therapies capable 
of inducing ICD can instigate a tumor-specific anti-
tumor response through activation of dendritic cells 
and consequent activation of specific T-cell activity.
Local immunotherapy of cancer capable of medi-
ating abscopal effects, and hence long-term protec-
tion from metastatic relapse, holds great potential for 
therapeutic intervention in oncology [36]. By repro-
gramming the tumor microenvironment through the 
eradication of local immune suppressive cells such as 
regulatory T cells (Tregs) followed by the infiltration 
of cancer killing CD8+ cytotoxic T cells (CTLs), one 
may reinstate systemic anticancer immune responses, 
hence eliminating all deposits of neoplastic cells. The 
intratumoral treatment of solid tumors with LTX-315 
has resulted in growth inhibition, complete regression 
and long-lasting tumor-specific immune responses 
in a variety of different experimental animal mod-
els. Typically, tumors ranging from 60 to 100 mm3 
were injected with 20 mg/ml LTX-315 at a volume of 
50 μl (1 mg/injection) once per day for three consecu-
tive days without any sign of systemic adverse events 
observed.
LTX-315 induces ICD through its membranolytic 
mode of action, leading to the release of potent immuno-
stimulants in addition to a wide spectrum of tumor anti-
gens, thus creating an essential premise for  tumor-specific 
immune responses.
Figure 2. LTX-315 induces immunogenic cell death in cancer cells. When treated with LTX-315, dying cancer cells 
release DAMPs such as calreticulin, ATP, HMGB1, mtDNA and formyl peptides. DAMPs bind to specific receptors on 
antigen-presenting cells such as dendritic cells and promotes their maturation and engulfment of tumor-antigens 
with subsequent presentation to T cells and execution of effective immune response. 
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Intratumoral treatment with LTX-315 resulted in a 
complete regression of orthotopic B16 melanomas in 
80% of animals. LTX-315-treated tumors harvested 
for immunohistochemistry displayed a significant 
increase in tumor-infiltrating T cells (TILs) and a 
change in TIL distribution in the tumor microenvi-
ronment, going from a peritumoral location to a more 
intratumoral location over time. Moreover, when pre-
viously cured animals were rechallenged with viable 
tumor cells they demonstrated a systemic protec-
tion against tumor formation, both orthotopically 
in the skin and in a lung metastasis model in which 
the tumor cells were injected intravenously 9 months 
 post-treatment [31].
The treatment of tumors with LTX-315 leads to a 
disintegration of the plasma membrane and cytoplas-
mic organelles with a subsequent release of DAMPs 
such as ATP, calreticulin, HMGB1 and cytochrome c, 
(Figure 2) in addition to tumor antigens, including neo-
antigens [32,33,37,38]. This results in an increase in TILs, 
TIL clonality and the number of clones with greater 
abundance in the tumor microenvironment. The 
treatment with LTX-315 also reprograms the tumor 
microenvironment by decreasing the local abundance 
of immunosuppressive Tregs and myeloid-derived 
suppressor cells [37].
Furthermore, an abscopal effect on nontreated 
lesions has been observed. When mesenchymal sub-
cutaneous sarcomas in PVG rats (rTMSCs) were 
injected with LTX-315, all animals treated went 
into complete remission. More remarkably, when 
only one out of three lesions in a three-tumor model 
mimicking tumor cell dissemination and metastasis 
was treated with LTX-315, both the treated lesion 
and the disseminated tumors were eradicated. Non-
treated lesions were heavily infiltrated with CD3+ 
and CD8+ T cells, consequently indicating a strong 
and immediate systemic effect following the LTX-
315-based therapy [Nestvold J, Wang M-Y, Camilio K et al. 
Oncolytic peptide LTX-315 induces an immune-mediated 
abscopal effect in a rat sarcoma model; Manuscript in prepa-
ration].
Long-term protective immune responses were fur-
ther demonstrated as previously cured animals were 
protected against s.c. and i.p. rechallenge 14 months 
after treatment. In addition, adoptive transfer of 
splenocytes allowed for transfer of the protective 
immunity of cured animals to irradiated naive recip-
ients. Moreover, the transferred protective immunity 
was tumor-specific, preventing the tumor formation 
of rTMSCs though not Roser’s T-cell leukemia after 
s.c. inoculation [Nestvold J, Wang M-Y, Camilio K  et  al. 
Oncolytic peptide LTX-315 induces an immune-mediated 
abscopal effect in a rat sarcoma model; Manuscript in prepa-
ration].
Emerging data indicate a correlation between pre-exist-
ing T-cell content in the tumortumor microenvironment, 
in particular the cytotoxic CD8+ T cells, and clinical 
response. Thus, patients with tumors who lack immune 
T-cell infiltration, so-called ‘cold’ tumors, require certain 
therapeutic interventions to restore T-cell entry, which 
enables responsiveness to immunotherapy [39].
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The ability of LTX-315 to increase T-cell infiltra-
tion, clonality and the diversity of T cells indicates 
that LTX-315 has a potential to reshape the tumor 
microenvironment, which makes LTX-315 potentially 
ideal as a combination partner for other immuno-
therapies, including immune checkpoint inhibitors 
(anti-CTLA4/anti-PD-1).
Indeed, in some preclinical tumor models, a com-
bination of LTX-315 and immune checkpoint inhibi-
tors (anti-CTLA4) demonstrates a significant syn-
ergy. Yamazaki et al [37] showed that LTX-315 acted 
as an immunogenic cytotoxic compound in vivo 
when used locally against MCA205 sarcomas. Small 
MCA205 tumors (20–25 mm2) went into complete 
regression when treated intratumorally with LTX-
315. The LTX-315-mediated anticancer effects were 
shown to be CD4+- and CD8+-T-cell-dependent as 
depletion experiments demonstrated that the removal 
of these cells abrogated the antitumor effects. In 
addition, treatment with LTX-315 increased the 
intratumoral ratio of CTLs over Tregs. Furthermore, 
when treating larger MCA205 sarcomas (>40 mm2) 
with LTX-315 in combination with CTLA4 mAb, a 
significant synergistic effect was observed. Peptide 
therapy demonstrated that membrane CTLA4 mol-
ecules were clearly upregulated by the peptide. An 
initial treatment with CTLA4 blockade followed by 
LTX-315 exhibited a major synergistic interaction, 
compared with either monotherapy. When both 
therapies were injected locally, Yamazaki and co-
workers obtained a strong therapeutic synergy, both 
on ipsilateral and contralateral MCA205 sarcomas. 
This demonstrates that LTX-315 is capable of mark-
edly enhancing the immune-mediated anticancer 
effects induced by CTLA4 blockade, even in tumors 
that were primarily resistant to CTLA4 mAb [37].
Other potential combination therapies or applica-
tions will become of high interest as well, for example 
combinations with adoptive T-cell therapies, CAR-T 
cell-therapy etc. These therapies are dependent on 
the isolation and extraction of high-quality T cells 
(from ‘hot’ tumors) in order to produce tumor-
specific T cells of a proper quality that can be rein-
troduced back to the patient. This so-called ‘T-cell 
primer’ application would further increase the poten-
tial use of LTX-315. Finally, in preclinical models, 
a combination of LTX-315 and chemotherapeutic 
agents, such as cyclophosphamide and doxorubicin 
exhibits significant synergy compared with either 
monotherapy [40].
The primary objective of local oncolytic therapies is 
to induce immunogenic cancer cell death in order to 
stimulate a tumor-specific immune response against 
residual cancer cells. The unique membranolytic 
mode of action of LTX-315 leads to the release of dan-
ger signals or damage-associated molecular pattern 
molecules and tumor antigens. These potent immu-
nostimulants prompt the recruitment and activation 
of professional antigens presenting cells such as den-
dritic cells which, in turn, can process and present the 
released tumor antigens and neoantigens to T cells. 
The subsequent T-cell activation and tumor-specific 
immune responses are characteristics essential for an 
abscopal effect against nontreated distant lesions and 
long-lasting immune protection against metastatic 
relapse.
In addition to a modest and predictable safety pro-
file, promising Phase I clinical data has demonstrated 
to date that LTX-315 induces a partial and complete 
regression in injected tumors, durable stable disease 
(global tumor response by CT scan) and significant 
increases in TILs, indicating a systemic immune 
response in some patients [41].
A Phase Ib study combining LTX-315 with ipilim-
umab (anti-CTLA4) in malignant melanoma patients, 
as well as LTX-315 with pembrolizumab (anti-PD-1) 
in metastatic breast cancer patients is ongoing.
Future perspective
LTX-315 is a first-in-class oncolytic peptide for intra-
tumoral injection. Previous data have shown that 
LTX-315 has the potential to stimulate anticancer 
immune responses in experimental preclinical ani-
mal models. Local treatment of tumor results in 
increased T-cell infiltration and anticancer immune 
responses that also suppress growth of distant tumors 
(abscopal effect). Thus, LTX-315 is ideal as a com-
bination partner for other immunotherapies, includ-
ing immune checkpoint inhibitors (anti-CTLA4/
anti-PD-1).
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Executive summary
•	 Oncolytic 9-mer cationic peptides were designed based on SAR-studies on the cationic antimicrobial peptide 
bovine lactoferricin.
•	 One candidate, LTX-315 was shown to be highly effective against a broad panel of both drug-resistant and 
drug-sensitive cancer cells with lower activity against normal cells.
•	 LTX-315 induces immunogenic cell death as defined through the release of danger-associated molecular 
patterns from tumor cells with subsequent activation of specific antitumor immune responses.
•	 Intratumoral administration of LTX-315 in animal models results in tumor necrosis and the infiltration of 
immune cells into the tumor tissue followed by complete remission of tumor.
•	 Treatment with LTX-315 reshapes the tumor microenvironment by decreasing the local abundance of 
immunosuppressive cells and increasing the frequency of effector T cells.
•	 The ability of LTX-315 to reshape the tumor microenvironment makes it potentially ideal as a combination 
partner for other immunotherapies, such as immune checkpoint inhibitors (anti-CTLA4/anti-PD-1).
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